Verition Fund Management
BEAM icon

Verition Fund Management’s Beam Therapeutics BEAM Stock Holding History

Verition Fund Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,375
Closed -$729K – 3335
2024
Q4 		$729K Buy
29,375
+14,351
+96% +$366K ﹤0.01% 2238
2024
Q3 		$368K Buy
+15,024
New +$388K ﹤0.01% 2515
2024
Q2 		– Sell
-7,894
Closed -$261K – 2990
2024
Q1 		$261K Buy
+7,894
New +$246K ﹤0.01% 2367
2022
Q4 		– Sell
-6,874
Closed -$327K – 2155
2022
Q3 		$327K Sell
6,874
-1,429
-17% -$81.5K ﹤0.01% 2158
2022
Q2 		$321K Sell
8,303
-4,521
-35% -$180K 0.01% 1701
2022
Q1 		$735K Buy
12,824
+6,471
+102% +$424K 0.01% 1672
2021
Q4 		$506K Buy
6,353
+2,472
+64% +$212K ﹤0.01% 1696
2021
Q3 		$338K Sell
3,881
-2,400
-38% -$241K ﹤0.01% 1416
2021
Q2 		$808K Buy
+6,281
New +$500K 0.01% 890

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Verition Fund Management's BEAM Position: Q1 2025 in Review

Verition Fund Management sold out of Beam Therapeutics (BEAM) in Q1 2025, closing a stake of 29,375 shares — an estimated $729K sold.

Verition Fund Management first reported a position in BEAM in Q2 2021 and held it in 9 quarters. The position peaked at $808K in Q2 2021. 238 funds tracked by Wall St. Rank hold BEAM as of Q1 2025.

  • Verition Fund Management reported no remaining Beam Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 29,375 Beam Therapeutics shares in Q1 2025, an estimated $729K.
  • Verition Fund Management first reported a position in Beam Therapeutics in Q2 2021 and held it in 9 quarters.
  • Verition Fund Management's Beam Therapeutics position peaked at $808K in Q2 2021.
  • 238 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.